|
gptkbp:instanceOf
|
gptkb:antibiotic
|
|
gptkbp:approvalYear
|
1991
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:J01FA09
|
|
gptkbp:availableOn
|
gptkb:tablet
oral suspension
extended-release tablet
|
|
gptkbp:bioavailability
|
50%
|
|
gptkbp:brand
|
gptkb:Biaxin
gptkb:Klaricid
|
|
gptkbp:CASNumber
|
81103-11-9
|
|
gptkbp:category
|
gptkb:Essential_medicine_(WHO)
|
|
gptkbp:chemicalFormula
|
C38H69NO13
|
|
gptkbp:contraindication
|
concomitant use with certain statins
hypersensitivity to macrolides
|
|
gptkbp:developedBy
|
gptkb:Japan
|
|
gptkbp:discoveredBy
|
gptkb:Taisho_Pharmaceutical
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:halfLife
|
3–7 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
clarithromycin
|
|
gptkbp:interactsWith
|
gptkb:ergot_alkaloids
gptkb:theophylline
gptkb:warfarin
gptkb:carbamazepine
gptkb:digoxin
statins
colchicine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits bacterial protein synthesis
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
747.96 g/mol
|
|
gptkbp:patent
|
1980
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
70–80%
|
|
gptkbp:PubChem_CID
|
84029
CHEMBL1741
DB01211
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
diarrhea
abdominal pain
headache
taste disturbance
|
|
gptkbp:UNII
|
HNZ1QN68KG
|
|
gptkbp:usedFor
|
skin infections
bacterial infections
respiratory tract infections
Helicobacter pylori eradication
|
|
gptkbp:bfsParent
|
gptkb:Erythromycin
gptkb:Macrolides
gptkb:CYP3A4
gptkb:Lipitor
|
|
gptkbp:bfsLayer
|
5
|